DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma
Latest Information Update: 10 Oct 2024
At a glance
- Drugs DT 2216 (Primary) ; Irinotecan
- Indications Carcinoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 08 Oct 2024 New trial record